Technical Analysis for ACOR - Acorda Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
ACOR closed up 1.01 percent on Thursday, January 18, 2018, on 1.95 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
|See historical ACOR trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||Shooting Star Candlestick||Bearish||0.00%|
|Jan 18||Lizard Bearish||Bearish Day Trade Setup||0.00%|
|Jan 18||Doji - Bearish?||Reversal||0.00%|
|Jan 18||Upper Bollinger Band Walk||Strength||0.00%|
|Jan 18||Wide Bands||Range Expansion||0.00%|
|Jan 18||Upper Bollinger Band Touch||Strength||0.00%|
|Jan 17||Upper Bollinger Band Walk||Strength||1.01%|
|Jan 17||Wide Bands||Range Expansion||1.01%|
|Jan 16||Bearish Engulfing||Bearish||-0.20%|
|Jan 16||New Uptrend||Bullish||-0.20%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ACOR news...
|52 Week High||33.0|
|52 Week Low||13.6|
|200-Day Moving Average||20.9133|
|50-Day Moving Average||22.368|
|20-Day Moving Average||22.985|
|10-Day Moving Average||24.08|
|Average True Range||1.3555|
|Chandelier Exit (Long, 3 ATRs )||22.9335|
|Chandelier Exit (Short, 3 ATRs )||24.5665|
|Upper Bollinger Band||26.0609|
|Lower Bollinger Band||19.9091|
|Percent B (%b)||0.83|
|MACD Signal Line||0.5715|
|Market Cap||1.16 Billion|
|Num Shares||46.6 Million|
|Price-to-Earnings (P/E) Ratio||-26.60|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||28.90|
|Resistance 3 (R3)||29.13||28.07||28.25|
|Resistance 2 (R2)||28.07||27.07||27.95||28.03|
|Resistance 1 (R1)||26.53||26.46||27.30||26.30||27.82|
|Support 1 (S1)||23.93||24.47||24.70||23.70||22.18|
|Support 2 (S2)||22.87||23.86||22.75||21.97|
|Support 3 (S3)||21.33||22.87||21.75|
|Support 4 (S4)||21.10|